The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 207 (2) ◽  
pp. 420-427 ◽  
Author(s):  
Nicola Normanno ◽  
Antonella De Luca ◽  
Monica R. Maiello ◽  
Manuela Campiglio ◽  
Maria Napolitano ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Mapk Pathway ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib

2006 ◽  
Vol 102 (3) ◽  
pp. 275-282 ◽  
Author(s):  
Monica R. Maiello ◽  
Amelia D’Alessio ◽  
Antonella De Luca ◽  
Adele Carotenuto ◽  
Anna Maria Rachiglio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Intrinsic Resistance ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

scholarly journals Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer

2019 ◽  
Vol 27 (8) ◽  
pp. 871-877 ◽  
Author(s):  
Xinwen Wang ◽  
Fupeng Zhang ◽  
Xi Yang ◽  
Meiping Xue ◽  
Xiaoli Li ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Second Generation ◽  
Kinase Inhibitor ◽  
Lung Cancer Cells ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase ◽  
Secreted Phosphoprotein 1

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), afatinib, has been approved for treating EGFR mutant lung cancer patients, but the mechanism of acquired resistance to afatinib has not been well studied. In this study, we established afatinib acquired resistant cell lines. Gene array technology was used to screen changes in gene expression between afatinib-resistant lung cancer cells and parental cells. Our results showed that secreted phosphoprotein 1 (SPP1) was significantly increased in afatinib-resistant lung cancer cells. To study the effect of SPP1 on afatinib resistance, siSPP1 was used to knock down SSP1 in afatinib-resistant lung cancer cells. Then sensitivity to afatinib and invasive ability were studied. We found that knockdown of SPP1 increased sensitivity of lung cancer cells to afatinib and decrease the ability of invasion. Of clinical significance, we found that SSP1 was upregulated in lung cancer tissues compared with adjacent normal tissues, and low level of SSP1 was strongly associated with better overall survival. Our results suggest that SPP1 enhanced the second-generation EGFR TKI resistance in lung cancer, and inhibiting SPP1 might be a therapeutic target to overcome afatinib resistance.

scholarly journals ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells

2011 ◽  
Vol 132 (1) ◽  
pp. 109-119 ◽  
Author(s):  
Katherine M. Aird ◽  
Jennifer L. Allensworth ◽  
Ines Batinic-Haberle ◽  
H. Kim Lyerly ◽  
Mark W. Dewhirst ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Inflammatory Breast Cancer ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor ◽  
Induced Apoptosis

scholarly journals Ganoderma lucidum Combined with the EGFR Tyrosine Kinase Inhibitor, Erlotinib Synergize to Reduce Inflammatory Breast Cancer Progression

2016 ◽  
Vol 7 (5) ◽  
pp. 500-511 ◽  
Author(s):  
Ivette J. Suárez-Arroyo ◽  
Tiffany J. Rios-Fuller ◽  
Yismeilin R. Feliz-Mosquea ◽  
Mercedes Lacourt-Ventura ◽  
Daniel J. Leal-Alviarez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Progression ◽  
Inflammatory Breast Cancer ◽  
Ganoderma Lucidum ◽  
Kinase Inhibitor ◽  
Breast Cancer Progression ◽  
Egfr Tyrosine Kinase Inhibitor ◽  
Egfr Tyrosine Kinase

scholarly journals A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells

2012 ◽  
Vol 318 (16) ◽  
pp. 2014-2021 ◽  
Author(s):  
Courtney R. Giordano ◽  
Kelly L. Mueller ◽  
Laura J. Terlecky ◽  
Kendra A. Krentz ◽  
Aliccia Bollig-Fischer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Tyrosine Kinase Inhibitor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Kinase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document